Trial Profile
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2020
Price :
$35
*
At a glance
- Drugs Foscarbidopa/Foslevodopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 01 May 2020 Preliminary results (n=13) characterizing pharmacokinetics, safety and tolerability of Levodopa in patients with parkinsons disease were presented at the 72nd Annual Meeting of the American Academy of Neurology
- 13 Nov 2019 Status changed from recruiting to completed.
- 30 Apr 2019 According to the AbbVie media release, data from this trial will be presented at the American Academy of Neurology Annual Meeting 2019.